{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:26:42Z","timestamp":1773296802986,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,5,22]],"date-time":"2017-05-22T00:00:00Z","timestamp":1495411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,5,22]],"date-time":"2017-05-22T00:00:00Z","timestamp":1495411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1038\/bmt.2017.88","type":"journal-article","created":{"date-parts":[[2017,5,22]],"date-time":"2017-05-22T13:40:54Z","timestamp":1495460454000},"page":"1120-1125","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party"],"prefix":"10.1038","volume":"52","author":[{"given":"L","family":"Bento","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Boumendil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Finel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Le Gouill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Amorim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Monjanel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Bouabdallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J O","family":"Bay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Nicolas-Virelizier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"McQuaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Ceballos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3739-7502","authenticated-orcid":false,"given":"A","family":"Rambaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Bachy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Malladi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Orchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Pohlreich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Tilly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1544-9911","authenticated-orcid":false,"given":"F","family":"Bonifazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X","family":"Poir\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Guilhot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Haenel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Crawley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Metzner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Gribben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N H","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Damaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Dreger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Montoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,22]]},"reference":[{"key":"BFbmt201788_CR1","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.3324\/haematol.2013.084723","volume":"98","author":"S Montoto","year":"2013","unstructured":"Montoto S, Corradini P, Dreyling M, Ghielmini M, Kimby E, L\u00f3pez-Guillermo A et al. Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party. Haematologica 2013; 98: 1014\u20131021.","journal-title":"Haematologica"},{"key":"BFbmt201788_CR2","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1093\/annonc\/mdu440","volume":"25","author":"I El-Najjar","year":"2014","unstructured":"El-Najjar I, Boumendil A, Luan JJ, Bouabdallah R, Thomson K, Mohty M et al. The impact of total body irradiation on the outcome of patients with follicular lymphoma treated with autologous stem-cell transplantation in the modern era: a retrospective study of the EBMT Lymphoma Working Party. Ann Oncol 2014; 25: 2224\u20132229.","journal-title":"Ann Oncol"},{"key":"BFbmt201788_CR3","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1038\/sj.leu.2404850","volume":"21","author":"S Montoto","year":"2007","unstructured":"Montoto S, Canals C, Rohatiner AZS, Taghipour G, Sureda A, Schmitz N et al. Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia 2007; 21: 2324\u20132331.","journal-title":"Leukemia"},{"key":"BFbmt201788_CR4","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1200\/JCO.2006.09.8327","volume":"25","author":"AZS Rohatiner","year":"2007","unstructured":"Rohatiner AZS, Nadler L, Davies AJ, Apostolidis J, Neuberg D, Matthews J et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol 2007; 25: 2554\u20132559.","journal-title":"J Clin Oncol"},{"key":"BFbmt201788_CR5","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1200\/JCO.2012.47.1862","volume":"31","author":"R Pettengell","year":"2013","unstructured":"Pettengell R, Schmitz N, Gisselbrecht C, Smith G, Patton WN, Metzner B et al. Rituximab purging and\/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2013; 31: 1624\u20131630.","journal-title":"J Clin Oncol"},{"key":"BFbmt201788_CR6","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1200\/JCO.2012.45.9453","volume":"31","author":"JM Vose","year":"2013","unstructured":"Vose JM, Carter S, Burns LJ, Ayala E, Press OW, Moskowitz CH et al. Phase III randomized study of rituximab\/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab\/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT C. J Clin Oncol 2013; 31: 1662\u20131668.","journal-title":"J Clin Oncol"},{"key":"BFbmt201788_CR7","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1182\/blood-2003-02-0622","volume":"102","author":"AK Gopal","year":"2003","unstructured":"Gopal AK, Gooley TA, Maloney DG, Petersdorf SH, Eary JF, Rajendran JG et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood 2003; 102: 2351\u20132357.","journal-title":"Blood"},{"key":"BFbmt201788_CR8","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1200\/JCO.2008.19.2245","volume":"27","author":"JN Winter","year":"2009","unstructured":"Winter JN, Inwards DJ, Spies S, Wiseman G, Patton D, Erwin W et al. Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol 2009; 27: 1653\u20131659.","journal-title":"J Clin Oncol"},{"key":"BFbmt201788_CR9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00277-006-0207-0","volume":"86","author":"M Dreyling","year":"2007","unstructured":"Dreyling M, Tr\u00fcmper L, von Schilling C, Rummel M, Holtkamp U, Waldmann A et al. Results of a national consensus workshop: therapeutic algorithm in patients with follicular lymphoma\u2014role of radioimmunotherapy. Ann Hematol 2007; 86: 81\u201387.","journal-title":"Ann Hematol"},{"key":"BFbmt201788_CR10","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.3109\/10428194.2011.570396","volume":"52","author":"TE Witzig","year":"2011","unstructured":"Witzig TE, Fishkin P, Gordon LI, Gregory SA, Jacobs S, Macklis R et al. Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report. Leuk Lymphoma 2011; 52: 1188\u20131199.","journal-title":"Leuk Lymphoma"},{"key":"BFbmt201788_CR11","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.clml.2011.03.007","volume":"11","author":"D Decaudin","year":"2011","unstructured":"Decaudin D, Mounier N, Tilly H, Ribrag V, Ghesqui\u00e8res H, Bouabdallah K et al. (90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study. Clin Lymphoma Myeloma Leuk 2011; 11: 212\u2013218.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Suppl 2","key":"BFbmt201788_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1634\/theoncologist.2009-S2-41","volume":"14","author":"C Gisselbrecht","year":"2009","unstructured":"Gisselbrecht C, Vose J, Nademanee A, Gianni AM, Nagler A . Radioimmunotherapy for stem cell transplantation in non-Hodgkin\u2019s lymphoma: in pursuit of a complete response. Oncologist 2009; 14 (Suppl 2): 41\u201351.","journal-title":"Oncologist"},{"key":"BFbmt201788_CR13","doi-asserted-by":"publisher","first-page":"v83","DOI":"10.1093\/annonc\/mdw400","volume":"27","author":"M Dreyling","year":"2016","unstructured":"Dreyling M, Ghielmini M, Rule S, Salles G, Vitolo U, Ladetto M et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27: v83\u2013v90.","journal-title":"Ann Oncol"},{"key":"BFbmt201788_CR14","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1200\/JCO.2009.27.7863","volume":"28","author":"F Morschhauser","year":"2010","unstructured":"Morschhauser F, Kraeber-Bod\u00e9r\u00e9 F, Wegener WA, Harousseau JL, Petillon MO, Huglo D et al. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter phase I\/II study in non-Hodgkin's lymphoma. J Clin Oncol 2010; 28: 3709\u20133716.","journal-title":"J Clin Oncol"},{"key":"BFbmt201788_CR15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1200\/JCO.2007.11.9248","volume":"26","author":"A Krishnan","year":"2008","unstructured":"Krishnan A, Nademanee A, Fung HC, Raubitschek AA, Molina A, Yamauchi D et al. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin\u2019s lymphoma. J Clin Oncol 2008; 26: 90\u201395.","journal-title":"J Clin Oncol"},{"key":"BFbmt201788_CR16","doi-asserted-by":"publisher","first-page":"2896","DOI":"10.1182\/blood-2005-03-1310","volume":"106","author":"A Nademanee","year":"2005","unstructured":"Nademanee A, Forman S, Molina A, Fung H, Smith D, Dagis A et al. A phase 1\/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 2005; 106: 2896\u20132902.","journal-title":"Blood"},{"key":"BFbmt201788_CR17","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.exphem.2007.01.043","volume":"35","author":"A Shimoni","year":"2007","unstructured":"Shimoni A, Zwas ST, Oksman Y, Hardan I, Shem-Tov N, Yerushalmi R et al. Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin\u2019s lymphoma. Exp Hematol 2007; 35: 534\u2013540.","journal-title":"Exp Hematol"},{"key":"BFbmt201788_CR18","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1002\/cncr.27418","volume":"118","author":"A Shimoni","year":"2012","unstructured":"Shimoni A, Avivi I, Rowe JM, Yeshurun M, Levi I, Or R et al. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancer 2012; 118: 4706\u20134714.","journal-title":"Cancer"},{"key":"BFbmt201788_CR19","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/annonc\/mds517","volume":"24","author":"M Ghielmini","year":"2013","unstructured":"Ghielmini M, Vitolo U, Kimby E, Montoto S, Walewski J, Pfreundschuh M et al. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol 2013; 24: 561\u2013576.","journal-title":"Ann Oncol"},{"key":"BFbmt201788_CR20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles G, Seymour JF, Offner F, L\u00f3pez-Guillermo A, Belada D, Xerri L et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011; 377: 42\u201351.","journal-title":"Lancet"},{"key":"BFbmt201788_CR21","doi-asserted-by":"publisher","first-page":"4285","DOI":"10.1200\/JCO.2006.09.2882","volume":"25","author":"MS Czuczman","year":"2007","unstructured":"Czuczman MS, Emmanouilides C, Darif M, Witzig TE, Gordon LI, Revell S et al. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol 2007; 25: 4285\u20134292.","journal-title":"J Clin Oncol"},{"key":"BFbmt201788_CR22","doi-asserted-by":"publisher","first-page":"4576","DOI":"10.1182\/blood-2004-12-4690","volume":"105","author":"JM Bennett","year":"2005","unstructured":"Bennett JM, Kaminski MS, Leonard JP, Vose JM, Zelenetz AD, Knox SJ et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood 2005; 105: 4576\u20134582.","journal-title":"Blood"},{"key":"BFbmt201788_CR23","doi-asserted-by":"publisher","first-page":"5175","DOI":"10.1200\/JCO.2008.16.8294","volume":"26","author":"L Devizzi","year":"2008","unstructured":"Devizzi L, Guidetti A, Tarella C, Magni M, Matteucci P, Seregni E et al. High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation. J Clin Oncol 2008; 26: 5175\u20135182.","journal-title":"J Clin Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt201788.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt201788","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/bmt.2017.88","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/bmt201788.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T20:05:21Z","timestamp":1648065921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt201788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,22]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["BFbmt201788"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2017.88","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,22]]},"assertion":[{"value":"7 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}